JUNCTION CITY, Kan., Nov. 27 /PRNewswire/ -- Ventria Bioscience announced today that Quentin B. Kubicek, Ph.D. would be joining the company as Director, Global Regulatory Affairs.
Dr. Kubicek joins Ventria with more than 20 years experience in regulatory affairs and policy development related to plant biotechnology. Prior to joining Ventria, Quentin worked with InterAmerican Institute for Cooperation on Agriculture (IICA) where he developed regulatory policies on behalf of several Latin American and Caribbean governments for products derived from biotechnology. Quentin has also held regulatory positions with Dupont Nutrition and Health and the United States Department of Agriculture. He received his Ph.D. in Molecular Biology from Texas A&M University.
"Quentin's proven leadership, scientific credentials and his experience working in regulatory affairs and policy development will help accelerate Ventria's growth as we achieve our vision for affordable healthcare solutions," said Scott Deeter, President and CEO, Ventria Bioscience. "Quentin will lead Ventria's Global Regulatory Affairs Group," he said.
"I am excited to be joining the Ventria team at a time of rapid growth so that I can utilize my experience to help Ventria achieve its vision of delivering affordable health care products to the global community," said Kubicek.
A recent child health study showed that Ventria's Lactiva and Lysomin helped reduce the duration of diarrhea in children by 30 percent when added to rehydration solutions. Childhood diarrhea is the second leading killer of children, claiming 2 million lives annually according to the World Health Organization.
For more information, see our website at Ventria Bioscience http://www.ventria.com
Statements in this announcement other than historical data and information constitute forward looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. Potential risks and uncertainties may include, but are not limited to, recent changes in senior management, fluctuations in operating results, market conditions and changes in technology and increased competition.
|SOURCE Ventria Bioscience|
Copyright©2007 PR Newswire.
All rights reserved